Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | SYK | P43405 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.53 |
| ▸ | FCER2 | P06734 | 1/20 | 0.53 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.53 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373158 | 0.93 | ERBB2 (0.59) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5358204 | 0.93 | ERBB2 (0.55) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5362073 | 0.93 | ERBB2 (0.70) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5363625 | 0.91 | ERBB2 (0.52) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5367619 | 0.88 | ERBB2 (0.68) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5365058 | 0.88 | ERBB2 (0.64) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5357858 | 0.86 | LRRK2 (0.65) | SYKNTRK1FCER2NTRK3NTRK2 | |
| SCHEMBL5367766 | 0.86 | GSK3B (0.61) | SYKNTRK1FCER2NTRK3NTRK2 | |
| SCHEMBL5361957 | 0.86 | ERBB2 (0.48) | ERBB2EGFRSYKNTRK1FCER2 | |
| SCHEMBL5367172 | 0.84 | ERBB2 (0.54) | ERBB2EGFRSYKLRRK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ERBB2 19/4885EGFR 286/4885SYK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.